Enliven Therapeutics ELVN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23.63M+17.2% | -$29.67M-28.0% | -$20.15M+13.0% | -$25.34M-27.0% | -$28.54M-25.5% | ||
| $14K-81.1% | $46K-42.5% | $62K-22.5% | $81K+3.8% | $74K-6.3% | ||
| $7.4M+8.8% | $12.31M+131% | $7.19M+38.8% | $7.72M+50.2% | $6.8M+50.6% | ||
| —— | -$26.5K-864% | -$26.5K-864% | -$26.5K-864% | -$26.5K-864% | ||
| -$519K-336% | $828K+156% | -$1.02M— | $789K— | $220K-89.8% | ||
| -$4.47M-79.0% | —— | —— | —— | -$2.5M+18.6% | ||
| -$97K-40.6% | -$91K-7.1% | -$90K-7.1% | -$87K-4.8% | -$69K+16.9% | ||
| -$19.29M+20.0% | -$15.84M+7.9% | -$13.28M-8.9% | -$17.06M+16.5% | -$24.13M-3.3% | ||
| $0-100% | —— | —— | $139K+6,850% | $20K0.0% | ||
| —— | $53.25K— | $53.25K— | $53.25K— | $53.25K— | ||
| $42.53M+2,880% | $0— | -$4.06M— | -$183.59M-445% | $1.43M+108% | ||
| $10.05M+4,196% | $528K— | $209K— | $1.32M— | $234K— | ||
| $10.05M+4,196% | $623K-98.4% | $0-100% | $218.38M+11,992% | $234K-99.7% | ||
| $33.29M+248% | -$2.84M-112% | -$17.71M-572% | —— | -$22.47M-146% | ||
| -$266K-691% | —— | $310K+144% | -$73K-112% | $45K-93.2% | ||
| $14K-81.1% | $46K-42.5% | $62K-22.5% | $81K+3.8% | $74K-6.3% | ||
| —— | -$26.5K-864% | -$26.5K-864% | -$26.5K-864% | -$26.5K-864% | ||
| -$4.47M-79.0% | —— | —— | —— | -$2.5M+18.6% | ||
| -$97K-40.6% | -$91K-7.1% | -$90K-7.1% | -$87K-4.8% | -$69K+16.9% | ||
| -$1.65M-1,184% | $694K— | —— | $398K-83.7% | $152K-95.8% | ||
| $93K+9.4% | $92K+13.6% | $89K+11.3% | $87K+8.8% | $85K+7.6% | ||
| —— | $53.25K— | $53.25K— | $53.25K— | $53.25K— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$97K-40.6% | -$91K-7.1% | -$90K-7.1% | -$87K-4.8% | -$69K+16.9% | ||
| $0-100% | —— | —— | —— | $736K— | ||
| $658K— | —— | $0+100% | $0-100% | $0-100% | ||
| -$19.29M+20.1% | -$15.84M+7.9% | -$13.28M-8.7% | -$17.2M+15.9% | -$24.15M-3.3% | ||
| -$19.29M+20.1% | -$15.84M+7.9% | -$13.28M-8.7% | -$17.2M+15.9% | -$24.15M-3.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Enliven Therapeutics generate?
- Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
- What is Enliven Therapeutics's free cash flow?
- After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
- Where does Enliven Therapeutics's cash flow data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.